As of June 30, 2025, Endonovo Therapeutics, Inc. carries a market capitalization of 193,058.29, placing it among publicly traded companies globally. Its enterprise value stands at 7.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 193,058.29 |
| Enterprise Value | 7.09M |
As of June 30, 2025, Endonovo Therapeutics, Inc. has 1.21B shares outstanding.
| Shares Outstanding | 1.21B |
These figures are as of June 30, 2025.
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.01 |
| P/FCF Ratio | 1.69 |
| P/OCF Ratio | 1.69 |
As of June 30, 2025, Endonovo Therapeutics, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -24.78, indicating conservative leverage, while an interest coverage ratio of -0.75 demonstrates limited ability to service its debt obligations.
| Debt / Equity | -24.78 |
| Debt / EBITDA | -7.40 |
| Interest Coverage | -0.75 |
These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -1,482.57, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -1,482.57 |
| Employee Count | 1.00 |
Over the twelve months ended June 30, 2025, Endonovo Therapeutics, Inc. generated - - in revenue and converted that into -2.46M in net income, yielding earnings per share of 0.00. EBITDA reached -932,060.00, while operating income came in at -1.23M.
| Gross Profit | -1.00 |
| Operating Income | -1.23M |
| Pretax Income | -2.46M |
| Net Income | -2.46M |
| EBITDA | -932,060.00 |
| EBIT | -1.23M |
As of June 30, 2025, Endonovo Therapeutics, Inc. holds 230.00 in cash and equivalents against 6.90M in total debt, resulting in a net debt position of 6.90M. Total book value stands at -27.82M, with working capital of -27.74M providing operational flexibility.
| Cash & Cash Equivalents | 230.00 |
| Total Debt | 6.90M |
| Net Debt | 6.90M |
| Equity (Book Value) | -27.82M |
| Book Value Per Share | -0.02 |
| Working Capital | -27.74M |
Endonovo Therapeutics, Inc. produced 76,629.00 in operating cash flow over the twelve months ended June 30, 2025.
| Operating Cash Flow | 76,629.00 |
| Free Cash Flow | 76,629.00 |
These figures cover the twelve months ended June 30, 2025. Free cash flow yield stands at 59.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 41.67, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Endonovo Therapeutics, Inc. shareholders.
| Shareholder Yield | 41.67 |
| FCF Yield | 59.03 |
Endonovo Therapeutics, Inc.'s most recent stock split took place on December 20, 2019 with a 1000:1 split ratio.
| Last Split Date | 12/20/2019 |
| Split Ratio | 1000:1 |
As of June 30, 2025, Endonovo Therapeutics, Inc. has an Altman Z-Score of -7,706.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7,706.95 |